TheEdgeResearch
Home / Stocks / CHB

Global X China Biotech Innovation ETF (CHB)

NASDAQ Financial Services Asset Management
$6.64 ▼ -0.38%
Market Cap
$1.4M
Sector
Financial Services
Industry
Asset Management
Beta
0.66
52-Wk Range
6.63-9.76
CEO
Country
US
Currency
USD

Global X China Biotech Innovation ETF operates in the Asset Management industry of the Financial Services sector, headquartered in New York, NY, US. The stock last traded at $6.64, down 0.38% on the session, giving a market capitalisation of $1.4M. Its beta of 0.66 implies it has historically moved less than the broad market.

Company profile
Exchange
NASDAQ Global Market
Employees
IPO date
2020-09-25
Headquarters
New York, NY, US
About Global X China Biotech Innovation ETF

This fund commits at least 80% of its overall assets, alongside any borrowed capital used for investment, to the securities tracked by its benchmark index. This also includes American and Global Depositary Receipts that are derived from those same index securities. The underlying index itself is specifically designed to provide investors with exposure to exchange-listed companies operating directly within China's biotechnology sector. Notably, this fund operates on a non-diversified basis.

Comparable companies

Global X China Biotech Innovation ETF is most often compared with the following Financial Services names:

GRZZHOMKPOPLJIMNIWMNXTVSDGSSMLETYNEWNDY
More research on CHB
CHB technical analysis CHB TheEdge Score Compare against peers
Open full interactive analysis & DCF →